Condensed Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Total revenue	$ 20,272	$ 9,266	$ 22,207	$ 22,993
Operating expenses:
Research and development	15,514	21,067	59,870	80,711
General and administrative	5,882	5,219	17,898	15,187
Total operating expenses	21,396	26,286	77,768	95,898
Operating loss	(1,124)	(17,020)	(55,561)	(72,905)
Other income, net	111	379	502	1,970
Loss before benefit from income taxes	(1,013)	(16,641)	(55,059)	(70,935)
Benefit from income taxes	0	132	0	436
Net Loss	$ (1,013)	$ (16,509)	$ (55,059)	$ (70,499)
Net Loss per share:
Basic and Diluted	$ (0.02)	$ (0.35)	$ (1.10)	$ (1.51)
Weighted average shares:
Basic and Diluted	50,114,710	46,885,424	50,031,615	46,803,659
Other comprehensive income (loss), net of tax of $0:
Change in unrealized gains (losses) on available-for-sale marketable securities	$ 6	$ (272)	$ (72)	$ 193
Total comprehensive loss	(1,007)	(16,781)	(55,131)	(70,306)
License and Milestone Fees
Revenue:
Total revenue	20,031	9,257	21,223	22,377
Collaborative Revenue
Revenue:
Total revenue			706
Clinical Compound Revenue
Revenue:
Total revenue	$ 241	$ 9	$ 278	$ 616